Ak Jain

The Appointments Committee of Cabinet has approved the appointment of Jain as CBDT Chairman, an order issued by Department of Personnel and Training (DoPT) said.

See 18-20% FY15 growth; formulations biz key driver: Ipca

The overall growth for FY14 would be around 18-20% and he expects similar growth for FY15 as well said AK Jain, ED, Ipca Labs.

See India biz grow 15%, exports to rise 25% in H2: Ipca

Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.

Ipca Lab gets final nod from USFDA for Indore SEZ plant

This is an establishment approval so it is a final approval from the US Food and Drug Administration (USFDA) for the Indore SEZ plant. Ipca Labs will start commercial production immediately from this plant.

May revise guidance upwards post Q2: Ipca Labs

AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.

Ipca Labs hopes to achieve 18-20% growth for FY12

AK Jain, the executive director of Ipca Labs, in an interview on CNBC-TV18, talks about the latest happenings in the company and sector.

Ipca Laboratories expects to clock 18-20% growth in FY12

AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.